De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Cigna Group Inkomsten in het verleden
Verleden criteriumcontroles 0/6
De winst van Cigna Group is gedaald met een gemiddeld jaarlijks percentage van -0.7%, terwijl de winst van de Healthcare -industrie jaarlijks groeide met 6.2%. De inkomsten zijn groeide met een gemiddeld percentage van 8.7% per jaar. Het rendement op het eigen vermogen Cigna Group bedraagt 9.6% en de nettomarge bedraagt 1.7%.
Belangrijke informatie
-0.7%
Groei van de winst
3.9%
Groei van de winst per aandeel
| Healthcare Groei van de industrie | 8.5% |
| Inkomstengroei | 8.7% |
| Rendement op eigen vermogen | 9.6% |
| Nettomarge | 1.7% |
| Volgende winstupdate | 31 Oct 2024 |
Recente prestatie-updates uit het verleden
Recent updates
These 4 Measures Indicate That Cigna Group (NYSE:CI) Is Using Debt Reasonably Well
Oct 14
Cigna: This Dividend Grower Could Be Worth Buying Now
Sep 26Returns On Capital Are Showing Encouraging Signs At Cigna Group (NYSE:CI)
Sep 26Cigna: Growth From Specialty Pharmacy And Care; Initiate With 'Buy'
Sep 19The Price Is Right For The Cigna Group (NYSE:CI)
Sep 08Cigna Group: Services Focus Leads To Outperformance
Jul 29Cigna: Game Over For PBMs?
Jul 12Cigna Group (NYSE:CI) Has A Somewhat Strained Balance Sheet
Jun 14Cigna: Will Benefit From Lower Medicaid Enrollments
Jun 11The Cigna Group (NYSE:CI) Not Lagging Market On Growth Or Pricing
May 27Cigna: An Up-And-Coming Dividend Growth Stock To Buy Now
May 13Cigna Group's (NYSE:CI) Soft Earnings Don't Show The Whole Picture
May 09Here's Why We Think The Cigna Group's (NYSE:CI) CEO Compensation Looks Fair for the time being
Apr 18Cigna: Time To Sell The Stock After A 50% Return? No, Here's Why
Apr 09Returns Are Gaining Momentum At Cigna Group (NYSE:CI)
Apr 05Cigna Continues To Reap Gains From A Shrewd Acquisition Made In 2018
Apr 01Cigna: Trimming The Fat And Staying Focused
Mar 05Cigna: Big Buybacks And Total Return Potential
Feb 26Cigna Group (NYSE:CI) Is Increasing Its Dividend To $1.40
Feb 05Cigna Q4 Preview: The Analysts' Whisper - Deciphering Cigna's Next Big Leap
Jan 29We Think Cigna Group (NYSE:CI) Can Stay On Top Of Its Debt
Jan 25Why Dividend Growth Investors Should Buy Cigna
Jan 18It's A Story Of Risk Vs Reward With The Cigna Group (NYSE:CI)
Jan 09Cigna Group (NYSE:CI) Is Experiencing Growth In Returns On Capital
Dec 25Cigna: Sentiment And Fundamentals On Their Side
Dec 21Cigna's Merger Fumble: A Festive Financial Rebound
Dec 11Humana And Cigna Topple On Rumors Of An Unlikely Union
Nov 30Cigna Delivering Growth At A Great Price
Nov 13Cigna: Too Cheap To Ignore
Oct 24We Think Cigna Group (NYSE:CI) Can Stay On Top Of Its Debt
Oct 06Cigna: Buy Rating Driven By Undervaluation & Revenue Growth
Oct 01Cigna Group (NYSE:CI) Is Reinvesting At Lower Rates Of Return
Sep 21Cigna: Seizing Opportunities And Managing Risks In The Healthcare Landscape
Sep 14Cigna Group: Weaker Than Peers But Still A Buy
Aug 27Cigna: Buy During The Next Correction (Technical Analysis)
Aug 08Cigna Group (NYSE:CI) Has A Pretty Healthy Balance Sheet
Jul 02Cigna: Buy While It's Still Cheap And Not Loved
Jun 29If EPS Growth Is Important To You, Cigna Group (NYSE:CI) Presents An Opportunity
Jun 18Cigna: Buy This Value Gem Before It Bounces Back
Jun 12Returns On Capital At Cigna Group (NYSE:CI) Paint A Concerning Picture
Jun 04Cigna: Many Reasons To Invest
May 29An Intrinsic Calculation For The Cigna Group (NYSE:CI) Suggests It's 49% Undervalued
May 21Is Cigna Group (NYSE:CI) A Risky Investment?
Mar 24Opbrengsten en kosten
Hoe Cigna Group geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 216,008 | 3,708 | 14,685 | 0 |
| 31 Mar 24 | 204,145 | 3,620 | 14,496 | 0 |
| 31 Dec 23 | 195,187 | 5,164 | 14,370 | 0 |
| 30 Sep 23 | 189,856 | 5,292 | 14,062 | 0 |
| 30 Jun 23 | 186,031 | 6,677 | 13,609 | 0 |
| 31 Mar 23 | 182,808 | 6,774 | 13,421 | 0 |
| 31 Dec 22 | 180,031 | 6,704 | 13,110 | 0 |
| 30 Sep 22 | 180,028 | 6,627 | 13,042 | 0 |
| 30 Jun 22 | 179,185 | 5,491 | 12,999 | 0 |
| 31 Mar 22 | 176,986 | 5,401 | 12,748 | 0 |
| 31 Dec 21 | 174,267 | 5,370 | 12,791 | 0 |
| 30 Sep 21 | 170,397 | 8,384 | 13,296 | 0 |
| 30 Jun 21 | 167,028 | 8,151 | 13,402 | 0 |
| 31 Mar 21 | 163,141 | 8,438 | 13,697 | 0 |
| 31 Dec 20 | 160,550 | 8,458 | 13,660 | 0 |
| 30 Sep 20 | 157,009 | 5,300 | 13,329 | 0 |
| 30 Jun 20 | 154,629 | 5,263 | 13,467 | 0 |
| 31 Mar 20 | 154,168 | 4,917 | 13,332 | 0 |
| 31 Dec 19 | 153,743 | 5,104 | 13,315 | 0 |
| 30 Sep 19 | 129,660 | 4,271 | 12,391 | 0 |
| 30 Jun 19 | 102,510 | 3,692 | 12,107 | 0 |
| 31 Mar 19 | 75,145 | 3,090 | 11,651 | 0 |
| 31 Dec 18 | 48,569 | 2,637 | 11,141 | 0 |
| 30 Sep 18 | 44,969 | 2,759 | 18,350 | 0 |
| 30 Jun 18 | 44,001 | 2,547 | 15,343 | 0 |
| 31 Mar 18 | 42,949 | 2,554 | 12,639 | 0 |
| 31 Dec 17 | 42,043 | 2,237 | 9,830 | 0 |
| 30 Sep 17 | 41,332 | 2,353 | 54 | 0 |
| 30 Jun 17 | 40,723 | 2,249 | 0 | 0 |
| 31 Mar 17 | 40,258 | 1,946 | 0 | 0 |
| 31 Dec 16 | 40,007 | 1,867 | 9,750 | 0 |
| 30 Sep 16 | 39,252 | 1,911 | 0 | 0 |
| 30 Jun 16 | 38,761 | 2,002 | 0 | 0 |
| 31 Mar 16 | 38,293 | 2,080 | 0 | 0 |
| 31 Dec 15 | 37,876 | 2,094 | 0 | 0 |
| 30 Sep 15 | 37,276 | 2,135 | 0 | 0 |
| 30 Jun 15 | 36,644 | 2,122 | 0 | 0 |
| 31 Mar 15 | 35,885 | 2,107 | 0 | 0 |
| 31 Dec 14 | 34,914 | 2,102 | 0 | 0 |
| 30 Sep 14 | 34,098 | 1,996 | 0 | 0 |
| 30 Jun 14 | 33,407 | 2,015 | 0 | 0 |
| 31 Mar 14 | 32,654 | 1,947 | 0 | 0 |
| 31 Dec 13 | 32,380 | 1,476 | 0 | 0 |
Kwaliteitswinsten: CI heeft een grote eenmalige verlies van $2.1B wat gevolgen heeft voor de financiële resultaten van de laatste 12 maanden tot 30th June, 2024.
Groeiende winstmarge: De huidige netto winstmarges (1.7%) CI } zijn lager dan vorig jaar (3.6%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: De winst van CI is de afgelopen 5 jaar met 0.7% per jaar gedaald.
Versnelling van de groei: De winstgroei CI is het afgelopen jaar negatief geweest en kan daarom niet worden vergeleken met het 5-jarig gemiddelde.
Winst versus industrie: CI had het afgelopen jaar een negatieve winstgroei ( -44.5% ), waardoor het moeilijk is om te vergelijken met het branchegemiddelde Healthcare ( 8% ).
Rendement op eigen vermogen
Hoge ROE: Het Rendement op eigen vermogen ( 9.6% ) van CI wordt als laag beschouwd.